125 related articles for article (PubMed ID: 22509763)
41. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
Quéro L; Giocanti N; Hennequin C; Favaudon V
Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
[TBL] [Abstract][Full Text] [Related]
42. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
43. Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer.
Nagata D; Yoshihiro H; Nakanishi M; Naruyama H; Okada S; Ando R; Tozawa K; Kohri K
Cancer Detect Prev; 2008; 32(3):259-66. PubMed ID: 18789607
[TBL] [Abstract][Full Text] [Related]
44. Antiandrogenic and growth inhibitory effects of ring-substituted analogs of 3,3'-diindolylmethane (ring-DIMs) in hormone-responsive LNCaP human prostate cancer cells.
Abdelbaqi K; Lack N; Guns ET; Kotha L; Safe S; Sanderson JT
Prostate; 2011 Sep; 71(13):1401-12. PubMed ID: 21321979
[TBL] [Abstract][Full Text] [Related]
45. Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists.
Yamamoto S; Matsunaga N; Hitaka T; Yamada M; Hara T; Miyazaki J; Santou T; Kusaka M; Yamaoka M; Kanzaki N; Furuya S; Tasaka A; Hamamura K; Ito M
Bioorg Med Chem; 2012 Jan; 20(1):422-34. PubMed ID: 22094279
[TBL] [Abstract][Full Text] [Related]
46. A bufadienolide derived androgen receptor antagonist with inhibitory activities against prostate cancer cells.
Tian HY; Yuan XF; Jin L; Li J; Luo C; Ye WC; Jiang RW
Chem Biol Interact; 2014 Jan; 207():16-22. PubMed ID: 24211617
[TBL] [Abstract][Full Text] [Related]
47. Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents.
Chen H; Yu YZ; Tian XM; Wang CL; Qian YN; Deng ZA; Zhang JX; Lv DJ; Zhang HB; Shen JL; Yuan M; Zhao SC
Bioorg Med Chem; 2019 Jan; 27(1):133-143. PubMed ID: 30482547
[TBL] [Abstract][Full Text] [Related]
48. Design and synthesis of novel steroidal imidazoles as dual inhibitors of AR/CYP17 for the treatment of prostate cancer.
Hou Q; He C; Lao K; Luo G; You Q; Xiang H
Steroids; 2019 Oct; 150():108384. PubMed ID: 30885648
[TBL] [Abstract][Full Text] [Related]
49. Second-generation testosterone-platinum(II) hybrids for site-specific treatment of androgen receptor positive prostate cancer: Design, synthesis and antiproliferative activity.
Ouellette V; Côté MF; Gaudreault RC; Tajmir-Riahi HA; Bérubé G
Eur J Med Chem; 2019 Oct; 179():660-666. PubMed ID: 31279298
[TBL] [Abstract][Full Text] [Related]
50. Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety.
Chen H; Zhang J; Hu P; Qian Y; Li J; Shen J
Bioorg Med Chem; 2019 Oct; 27(20):115081. PubMed ID: 31493989
[TBL] [Abstract][Full Text] [Related]
51. In silico selection and cell-based characterization of selective and bioactive compounds for androgen-dependent prostate cancer cell.
Cruz EC; Carecho AR; Saidel ME; Montanari CA; Leitão A
Bioorg Med Chem Lett; 2017 Feb; 27(3):546-550. PubMed ID: 28011219
[TBL] [Abstract][Full Text] [Related]
52. Synthesis and preliminary in vitro biological evaluation of 7α-testosterone-chlorambucil hybrid designed for the treatment of prostate cancer.
Bastien D; Hanna R; Leblanc V; Asselin É; Bérubé G
Eur J Med Chem; 2013 Jun; 64():442-7. PubMed ID: 23665800
[TBL] [Abstract][Full Text] [Related]
53. Arylisothiocyanato selective androgen receptor modulators (SARMs) for prostate cancer.
Hwang DJ; Yang J; Xu H; Rakov IM; Mohler ML; Dalton JT; Miller DD
Bioorg Med Chem; 2006 Oct; 14(19):6525-38. PubMed ID: 16828557
[TBL] [Abstract][Full Text] [Related]
54. "True" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancer.
Caboni L; Kinsella GK; Blanco F; Fayne D; Jagoe WN; Carr M; Williams DC; Meegan MJ; Lloyd DG
J Med Chem; 2012 Feb; 55(4):1635-44. PubMed ID: 22280402
[TBL] [Abstract][Full Text] [Related]
55. Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents.
Xu X; Ge R; Li L; Wang J; Lu X; Xue S; Chen X; Li Z; Bian J
Eur J Med Chem; 2018 Jan; 143():1325-1344. PubMed ID: 29117897
[TBL] [Abstract][Full Text] [Related]
56. Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment.
Liang JJ; Xie H; Yang RH; Wang N; Zheng ZJ; Zhou C; Wang YL; Wang ZJ; Liu HM; Shan LH; Ke Y
Bioorg Med Chem; 2021 Sep; 45():116331. PubMed ID: 34364224
[TBL] [Abstract][Full Text] [Related]
57. Novel peptidomimetic compounds containing redox active chalcogens and quinones as potential anticancer agents.
Shaaban S; Diestel R; Hinkelmann B; Muthukumar Y; Verma RP; Sasse F; Jacob C
Eur J Med Chem; 2012 Dec; 58():192-205. PubMed ID: 23124216
[TBL] [Abstract][Full Text] [Related]
58. Structure activity relationship studies of natural product chemokine receptor CCR5 antagonist anibamine toward the development of novel anti prostate cancer agents.
Zhang F; Arnatt CK; Haney KM; Fang HC; Bajacan JE; Richardson AC; Ware JL; Zhang Y
Eur J Med Chem; 2012 Sep; 55():395-408. PubMed ID: 22901310
[TBL] [Abstract][Full Text] [Related]
59. New phenstatin-fatty acid conjugates: synthesis and evaluation.
Chen J; Brown DP; Wang YJ; Chen ZS
Bioorg Med Chem Lett; 2013 Sep; 23(18):5119-22. PubMed ID: 23932339
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists.
Joseph JD; Wittmann BM; Dwyer MA; Cui H; Dye DA; McDonnell DP; Norris JD
Proc Natl Acad Sci U S A; 2009 Jul; 106(29):12178-83. PubMed ID: 19574450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
